What do you need to know before the release of DEXCOM’s earnings

DEXCOM, INC (DXCM), a San Diego-based medical device company, which is $ 32.5 billion in a market cap, specializes in continuous glucose monitoring (CGM) systems. Its technology includes a small, implantable sensor that follows glucose levels below the skin and transmits data to real-time external receptacle. DexCom Oral to inform the market in 2025 after the market was closed on Wednesday, July 30.

Analysts before the event are waiting for the DXCM to earn $ 0.45 per share, which will earn up to $ 0.43 per share in the year. The company defeated consensus assessments in two of the last four quarters while lost the forecast.

DXCM for full year, the DXCM is waiting for $ 2.03, 23.8% to EPS of $ 2.64 to 23.8% in 2024. His EPS is expected to increase by 24.6% of the year for $ 2026.

During the last 52 weeks, the shares of DXCM decreased by 25.2%, S & P 500s ($ SPX) 13.4% of the Gains and Health Sector SPDR Foundation (XLV) 5.4% 5.4% of 5.4%.

On July 1, DEXCOM shares fell by more than 4% after proposing to change the US government’s payment schedules and presented a competitive proposal program for diabetic devices affecting the pumping sector.

However, the consensus opinion of analysts the DXCM Foundation is very positive with the gross “strong purchase” rating. The Shares covers 25 analytics, 20 “strong purchases” rating, one gives one “a moderate purchase” and four “hold.” The average DCCM’s average analytical price is $ 99.68, 20.2% of the current levels indicate a potential subsection.

On the day, the critical wreck did not have any positions (either direct or indirect) of the securities marked in this article. All information and information in this article are for informational purposes only. This article was originally published Barchart.com